Earnings
Penumbra Revenue Climbs 15.6% To $410.1 Million, But Net Income Slips To $42.3 Million
Selling costs outran sales, and with the Boston Scientific deal pending, the company will give no 2026 outlook and hold no call.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Selling costs outran sales, and with the Boston Scientific deal pending, the company will give no 2026 outlook and hold no call.
SEC Filings
The company's investor deck puts the U.S. opportunity for ersodetug at about 6,000 patients, driven by weight-based dosing.
Deals
The company's quarterly report shows the revolver it already has could pay for part of the take-private, while buybacks have stopped.
Earnings
The elevator maker's repurchases stopped as New Equipment profit fell to $42 million and a €600 million euro bond comes due in December.
Earnings
A confidential water-pipe project drove record third-quarter sales while revolver debt rose to $18.5 million after the Serpentix purchase.
Markets
Shares rallied after record third-quarter adjusted earnings and a $40 adjusted EPS goal for 2030, though price-cost parity slipped to late 2026.
SEC Filings
The bank also added a new reserve adjustment for commercial-loan uncertainty and approved a $3.5 billion buyback authorization.
SEC Filings
Awards that vested below their grant-date price added $9 million of tax expense, against 38% a year earlier.
SEC Filings
The brokerage's revolver balance reached $616 million at September 30, and $2.5 billion of buyback room remains.
Insider Trades
The planned sale comes days after a separate 13,066-share sale that brought in $4,715,190, the same form shows.
Earnings
The $1.23 billion Vega write-off was not deductible, leaving Incyte with a $784.8 million third-quarter net loss despite 14% revenue growth.
SEC Filings
Hyatt drew $150 million on its revolver as cash slipped to $495 million and a loyalty-program tax case went back to Tax Court.